Compare SURG & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SURG | VNRX |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Advertising | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 31.9M |
| IPO Year | N/A | 2012 |
| Metric | SURG | VNRX |
|---|---|---|
| Price | $0.88 | $0.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.75 | $2.50 |
| AVG Volume (30 Days) | 157.4K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | $3.78 | $68.22 |
| Revenue Next Year | $113.46 | $382.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.75 | $0.17 |
| 52 Week High | $3.47 | $0.94 |
| Indicator | SURG | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.40 | 42.62 |
| Support Level | $0.75 | $0.17 |
| Resistance Level | $0.95 | $0.27 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 64.89 | 36.63 |
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.